Avapritinib (2) (Ayvakyt®) – Leukaemia, myeloid, acute (AML); mastocytosis; after at least 1 previous therapy

Characteristics

Start date 01.04.2022
Resolution 15.09.2022
INN Avapritinib
Brand name Ayvakyt®
Pharm. company Blueprint Medicines (Germany) GmbH
G-BA procedure ID 2022-04-01-D-798
Therapeutic area Oncological diseases ORPHAN
Reason for procedure New Indication
Regulatory status Conditional Approval

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasia (SM-AHN) or mast cell leukaemia (MCL) following at least one systemic therapy

Subpopulation Indication Comparator
Adults with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasia (SM-AHN) or mast cell leukaemia (MCL) following at least one systemic therapy Not applicable

9. Associated procedures



<< List of all resolutions